126 related articles for article (PubMed ID: 32850963)
1. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo.
van Huizen M; Bloeme-Ter Horst JR; de Gruyter HLM; Geurink PP; van der Heden van Noort GJ; Knaap RCM; Nelemans T; Ogando NS; Leijs AA; Urakova N; Mark BL; Snijder EJ; Myeni SK; Kikkert M
PLoS Pathog; 2024 Mar; 20(3):e1012100. PubMed ID: 38527094
[TBL] [Abstract][Full Text] [Related]
3. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
Swargiary A; Mahmud S; Saleh MA
J Biomol Struct Dyn; 2022 Mar; 40(5):2067-2081. PubMed ID: 33089730
[TBL] [Abstract][Full Text] [Related]
4. Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease.
Clasman JR; Everett RK; Srinivasan K; Mesecar AD
Antiviral Res; 2020 Feb; 174():104661. PubMed ID: 31765674
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 papain-like protease plays multiple roles in regulating cellular proteins in the endoplasmic reticulum.
Yang M; Mariano J; Su R; Smith CE; Das S; Gill C; Andresson T; Loncarek J; Tsai YC; Weissman AM
J Biol Chem; 2023 Dec; 299(12):105346. PubMed ID: 37838170
[TBL] [Abstract][Full Text] [Related]
6. Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease:
Pitsillou E; Liang J; Ververis K; Lim KW; Hung A; Karagiannis TC
Front Chem; 2020; 8():623971. PubMed ID: 33364229
[TBL] [Abstract][Full Text] [Related]
7. Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking.
Valdés-Albuernes JL; Díaz-Pico E; Alfaro S; Caballero J
Front Mol Biosci; 2024; 11():1374364. PubMed ID: 38601323
[TBL] [Abstract][Full Text] [Related]
8. Targeting papain-like protease by natural products as novel therapeutic potential SARS-CoV-2.
Waqas M; Ullah S; Halim SA; Rehman NU; Ali A; Jan A; Muhsinah AB; Khan A; Al-Harrasi A
Int J Biol Macromol; 2024 Feb; 258(Pt 1):128812. PubMed ID: 38114011
[TBL] [Abstract][Full Text] [Related]
9. Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro.
Shahid M; Alaofi AL; Ahmad Ansari M; Fayaz Ahmad S; Alsuwayeh S; Taha E; Raish M
Saudi Pharm J; 2024 Apr; 32(4):101986. PubMed ID: 38487020
[TBL] [Abstract][Full Text] [Related]
10. Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro.
Liu X; Zheng M; Zhang H; Feng B; Li J; Zhang Y; Zhang J; Zhao N; Li C; Song N; Song B; Yang D; Chen J; Qi A; Zhao L; Luo C; Zang Y; Liu H; Li J; Zhang B; Zhou Y; Zheng J
Antiviral Res; 2024 Jun; ():105944. PubMed ID: 38914283
[TBL] [Abstract][Full Text] [Related]
11. Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin.
Wydorski PM; Osipiuk J; Lanham BT; Tesar C; Endres M; Engle E; Jedrzejczak R; Mullapudi V; Michalska K; Fidelis K; Fushman D; Joachimiak A; Joachimiak LA
Nat Commun; 2023 Apr; 14(1):2366. PubMed ID: 37185902
[TBL] [Abstract][Full Text] [Related]
12. Entropy driven cooperativity effect in multi-site drug optimization targeting SARS-CoV-2 papain-like protease.
Duan L; Tang B; Luo S; Xiong D; Wang Q; Xu X; Zhang JZH
Cell Mol Life Sci; 2023 Oct; 80(11):313. PubMed ID: 37796323
[TBL] [Abstract][Full Text] [Related]
13. Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of SARS-CoV-2 PLpro Enzyme.
Sabadini G; Mellado M; Morales C; Mella J
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794177
[TBL] [Abstract][Full Text] [Related]
14. What Strengthens Protein-Protein Interactions: Analysis and Applications of Residue Correlation Networks.
Hung TI; Hsieh YJ; Lu WL; Wu KP; Chang CA
J Mol Biol; 2023 Dec; 435(24):168337. PubMed ID: 37918563
[TBL] [Abstract][Full Text] [Related]
15. What Strengthens Protein-Protein Interactions: Analysis and Applications of Residue Correlation Networks.
Hung TI; Hsieh YJ; Lu WL; Wu KP; Chang CA
Res Sq; 2023 Jun; ():. PubMed ID: 37333350
[TBL] [Abstract][Full Text] [Related]
16. What Strengthens Protein-Protein Interactions: Analysis and Applications of Residue Correlation Networks.
Hung TI; Hsieh YJ; Lu WL; Wu KP; Chang CA
bioRxiv; 2023 Jun; ():. PubMed ID: 36993448
[TBL] [Abstract][Full Text] [Related]
17. ATOMDANCE: Kernel-based denoising and choreographic analysis for protein dynamic comparison.
Babbitt GA; Rajendran M; Lynch ML; Asare-Bediako R; Mouli LT; Ryan CJ; Srivastava H; Rynkiewicz P; Phadke K; Reed ML; Moore N; Ferran MC; Fokoue EP
Biophys J; 2024 Mar; ():. PubMed ID: 38515299
[TBL] [Abstract][Full Text] [Related]
18. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
Rut W; Lv Z; Zmudzinski M; Patchett S; Nayak D; Snipas SJ; El Oualid F; Huang TT; Bekes M; Drag M; Olsen SK
Sci Adv; 2020 Oct; 6(42):. PubMed ID: 33067239
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of SARS-CoV-2 papain-like protease.
Gao X; Qin B; Chen P; Zhu K; Hou P; Wojdyla JA; Wang M; Cui S
Acta Pharm Sin B; 2021 Jan; 11(1):237-245. PubMed ID: 32895623
[TBL] [Abstract][Full Text] [Related]
20. The emerging SARS-CoV-2 papain-like protease: Its relationship with recent coronavirus epidemics.
Kandeel M; Kitade Y; Fayez M; Venugopala KN; Ibrahim A
J Med Virol; 2021 Mar; 93(3):1581-1588. PubMed ID: 32902889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
